Writing

The work behind the position.

Evidence, limitations and practical questions for people who want to understand the system before acting on it.

SequencingBefore Testosterone: What a Complete Workup Should EstablishA low result is one part of the question. Symptoms, repeat testing, draw conditions and the cause of the result are separate parts of the workup.

MeasurementWhy One Low Testosterone Result Is Not a DiagnosisTestosterone varies within the same person. A single result cannot carry the full weight of diagnosis, cause and treatment decisions.

MeasurementMorning, Fasting, Repeat: Why Draw Conditions MatterThe time and conditions of a blood draw can change what the result appears to say—especially when different tests are compared.

SequencingWhat Weight Loss Alone Has Been Associated With—And What It Cannot PredictPopulation research finds an association between weight loss and testosterone change. It does not provide a personal hormone forecast.

GLP-1Trial Results Are Not Personal Forecasts: Reading STEP 1 CorrectlyA clinical-trial average describes a defined study population under defined conditions. It is not a guaranteed result for the next person.

GLP-1Why GLP-1 Results in Real Life Differ From Clinical TrialsTrial design, participant selection, treatment persistence and missing data all affect the distance between published trial averages and real-world cohorts.

GLP-1What Happens After GLP-1 Treatment Stops?The STEP 1 extension followed participants after treatment withdrawal and found substantial average weight regain. The finding describes a cohort, not an individual destiny.

GLP-1Weight Loss and Lean Mass: What Body-Composition Research Actually ShowsScale weight does not identify what changed. Body-composition studies separate fat mass and lean mass, but neither term is identical to muscle function.

PeptidesThe July 2026 Peptide Vote: Advisory Is Not ApprovalAn advisory-committee discussion is one step in a regulatory process. It does not turn a compounded substance into an FDA-approved drug.

PeptidesBPC-157, TB-500 and Retatrutide: Regulatory Status vs Marketing ClaimsRegulatory status, available human evidence and online marketing claims are three different questions. Combining them produces misleading conclusions.

PositionsTRT IS A SEQUENCING QUESTION.Legitimate treatment, routinely started before the basics are measured or the diagnosis is confirmed.Read article

PositionsTRIAL RESULTS ARE NOT REAL-WORLD OUTCOMES.The distance between published results and everyday results is usually a question of execution, not chemistry.Read article

PositionsA NUMBER NEEDS ITS CONTEXT.Measurement is useful. Confidence in a single reading, stripped of method and context, is not.Read article

PositionsSTATUS, EVIDENCE AND MARKETING ARE THREE DIFFERENT THINGS.Regulatory status is a fact, evidence quality is a judgement, and marketing is neither.Read article